Startup profile · funding coverage
Rezo Therapeutics funding, valuation and investors
Biotech mapping disease networks from UCSF QBI tech for precision therapeutics.
Keep track of Rezo Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$78M · November 2022
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$78M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · San Francisco Bay Area, CA
Investors in latest funding
Overview
Rezo Therapeutics is a precision medicine biotech spun out of UCSF's Quantitative Biosciences Institute (QBI). Founded by renowned scientists including Nevan Krogan and Kevan Shokat, Rezo maps integrated disease networks using proteomics and genetics to identify novel drug targets. The company launched with a $78M Series A in November 2022 co-led by SR One, a16z Bio + Health, and Norwest Venture Partners. Rezo's platform connects protein interaction networks with genetic disease associations to find druggable nodes that single-target approaches miss. Based in the Bay Area, the company is building a pipeline of precision therapeutics across multiple disease areas. The scientific pedigree from UCSF QBI provides differentiated target discovery capabilities.
Why Rezo Therapeutics is interesting
Spun out Krogan/Shokat lab work integrating proteomics and genetics into druggable network maps — a16z Bio co-led launch with SR One.
Product & use cases
Rezo uses integrated disease network mapping — combining proteomics, genetics, and systems biology — to discover precision therapeutic targets from UCSF QBI technology.
- Novel drug target identification via disease network mapping
- Precision therapeutics development from systems biology insights
- Translating QBI academic research into clinical pipeline
Key facts
- Series A (Nov 2022): $78M co-led by SR One, a16z Bio + Health, and Norwest
- Spun out of UCSF Quantitative Biosciences Institute (QBI)
- Founded by scientists Nevan Krogan and Kevan Shokat
- Integrated disease network mapping platform for drug discovery
Funding history (newest first)
Investors in our directory
Funds linked from Rezo Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: UCSF QBI scientific foundation with Krogan/Shokat lab pedigree. Integrated network approach vs single-gene target discovery.
Systems biology drug discovery has produced mixed clinical results industry-wide. Rezo's QBI pedigree and $78M launch provide runway, but the field remains high-risk. Network-based target ID must translate to validated clinical candidates to differentiate from other computational biology approaches.
-
Recursion Pharmaceuticals adjacent
AI-driven drug discovery with phenomics; different technical approach.
-
Insitro adjacent
ML-driven drug discovery; also a16z Bio portfolio company.
-
Traditional pharma R&D incumbent
Internal target discovery; slower but better-resourced.
Notable stories
- Rezo launched with $78M from UCSF QBI research by Nevan Krogan and Kevan Shokat, applying integrated proteomics-genetics network mapping to drug discovery (company press, 2022).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Rezo Therapeutics's financing or category context.
FAQs about Rezo Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.